CYP26A1 Antibody (F27 P6 A1): sc-53618

CYP26A1 Antibody (F27 P6 A1) is a mouse monoclonal IgG antibody that detects CYP26A1 protein of mouse, rat, and human origin by western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and immunohistochemistry with paraffin-embedded sections (IHCP). CYP26A1 (F27 P6 A1) antibody is available in both non-conjugated and various conjugated forms, including agarose, horseradish peroxidase (HRP), phycoerythrin (PE), fluorescein isothiocyanate (FITC), and multiple Alexa Fluor® conjugates. CYP26A1, also known as retinoic acid-4-hydroxylase, is a crucial enzyme in retinoic acid catabolism, vital for regulating developmental processes and maintaining cellular homeostasis. By catalyzing retinoic acid hydroxylation, CYP26A1 helps modulate retinoic acid levels, preventing teratogenic effects during embryonic development. This regulation protects tailbud tissues from inappropriate retinoic acid levels, which can lead to severe developmental abnormalities. CYP26A1 transcription is epigenetically regulated by nuclear retinoic acid receptor β2, highlighting intricate control mechanisms governing expression. Mutations in CYP26A1 have been linked to various congenital disorders, including caudal agenesis and spina bifida, underscoring significance in developmental biology. CYP26A1 is upregulated in certain tumors, such as adenomatous polyposis coli mouse adenomas and human sporadic colon carcinomas, indicating potential roles in cancer biology and as a therapeutic target.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

CYP26A1 Antibody (F27 P6 A1) References:

1. Developing with lethal RA levels: genetic ablation of Rarg can restore the viability of mice lacking Cyp26a1.  |  Abu-Abed, S., et al. 2003. Development. 130: 1449-59. PMID: 12588859
2. CYP26A1 and CYP26C1 cooperate in degrading retinoic acid within the equatorial retina during later eye development.  |  Sakai, Y., et al. 2004. Dev Biol. 276: 143-57. PMID: 15531370
3. Regulation of CYP26A1 expression by selective RAR and RXR agonists in human NB4 promyelocytic leukemia cells.  |  Idres, N., et al. 2005. Biochem Pharmacol. 69: 1595-601. PMID: 15896339
4. Cytochrome p450 profile of colorectal cancer: identification of markers of prognosis.  |  Kumarakulasingham, M., et al. 2005. Clin Cancer Res. 11: 3758-65. PMID: 15897573
5. Transcriptional co-operativity between distant retinoic acid response elements in regulation of Cyp26A1 inducibility.  |  Loudig, O., et al. 2005. Biochem J. 392: 241-8. PMID: 16053444
6. Analysis of ALDH1A2, CYP26A1, CYP26B1, CRABP1, and CRABP2 in human neural tube defects suggests a possible association with alleles in ALDH1A2.  |  Deak, KL., et al. 2005. Birth Defects Res A Clin Mol Teratol. 73: 868-75. PMID: 16237707
7. RAR-mediated epigenetic control of the cytochrome P450 Cyp26a1 in embryocarcinoma cells.  |  Pozzi, S., et al. 2006. Oncogene. 25: 1400-7. PMID: 16261163
8. Mutational screening of the CYP26A1 gene in patients with caudal regression syndrome.  |  De Marco, P., et al. 2006. Birth Defects Res A Clin Mol Teratol. 76: 86-95. PMID: 16463413
9. Up-regulation of CYP26A1 in adenomatous polyposis coli-deficient vertebrates via a WNT-dependent mechanism: implications for intestinal cell differentiation and colon tumor development.  |  Shelton, DN., et al. 2006. Cancer Res. 66: 7571-7. PMID: 16885356
10. The glucocorticoid receptor represses, whereas C/EBPβ can enhance or repress CYP26A1 transcription.  |  Yoo, HS., et al. 2022. iScience. 25: 104564. PMID: 35789854
11. Cyp26a1 supports post-natal retinoic acid homeostasis and glucoregulatory control.  |  Yoo, HS., et al. 2023. J Biol Chem. 104669. PMID: 37011860
12. Metformin reduces hepatocarcinogenesis by inducing downregulation of Cyp26a1 and CD8+ T cells.  |  He, W., et al. 2023. Clin Transl Med. 13: e1465. PMID: 37997519

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-CYP26A1 Antibody (F27 P6 A1) has 11 citations in a variety of scientific publications.

Primary antibodies like Anti-CYP26A1 Antibody (F27 P6 A1) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

CYP26A1 Antibody (F27 P6 A1) Specifications

Alternate Product Name: CYP26A1

Product Clone Name: F27 P6 A1

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG kappa light chain

Amino Acids:

Epitope Target: CYP26A1

Epitope Species: human

Product Reactivity/Detection: CYP26A1

Species Reactivity/Detection: mouse, rat, human

Additional Mammalian Reactivity: N/A

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IP, IF, IHC(P)

Vialing Information: Each vial contains 200 µg IgG kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 11 citations in various scientific publications

Available Conjugates/Forms for CYP26A1 Antibody (F27 P6 A1): AC: Agarose, AF488: Alexa Fluor^® 488, AF546: Alexa Fluor^® 546, AF594: Alexa Fluor^® 594, AF647: Alexa Fluor^® 647, AF680: Alexa Fluor^® 680, AF790: Alexa Fluor^® 790, FITC: Fluoroscein, HRP: Horseradish Peroxidase, PE: Phycoerythrin